

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On Dec. 18, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: *J. Dallara*

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**



**PATENT**  
Attorney Docket No.: 02307O-126810US  
Client Reference No.: 2002-453-1

In re application of:

Dennis A. CARSON  
Michael D. ROSENBACH  
Carlos J. CARRERA

Application No.: 10/632,592

Filed: August 1, 2003

For: METHODS FOR INHIBITING  
PROTEIN KINASES IN CANCER  
CELLS

Examiner: Not Yet Assigned

Art Unit: 1651

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Dennis A. CARSON, Michael D. ROSENBACH,  
Carlos J. CARRERA  
Application No.: 10/632,592  
Page 2

PATENT

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kenneth A. Weber  
Reg. No. 31,677

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
BLK:mtd  
60079180 v1



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/632,592	
			Filing Date	August 1, 2003	
			First Named Inventor	Carson, Dennis A.	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	023070-126810US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,235,740 B1	05-22-2001	Barrish et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AB	WO	99/24035	A1	05-20-1999			<input type="checkbox"/>
	AC	WO	02/45717	A1	06-13-2002			<input type="checkbox"/>
	AD	EP	0359981	A1	08-10-1989			<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AE	LI, Wei, et al.; "Synergistic Action of Tiazofurin and Genistein in Human Ovarian Carcinoma Cells"; <u>Oncology Research</u> 1998 pp. 117-122 Vol. 10.	
	AF	NOE, Veronique, et al.; "Protein Kinase C Inhibitors Reduce Phorbol Ester-Induced Resistance to Methotrexate in Chinese Hamster Ovary Cells"; <u>Biochemical Pharmacology</u> 1995 pp. 337-346 Vol. 50 No. 3.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

60079180 v1